Special Issue "Phospholipases and Lipases: Targets for Drug Development"
Deadline for manuscript submissions: closed (28 February 2018).
Interests: synthesis and biological studies on anti-inflammatory and antioxidant agents, on inhibitors of enzymes implicated in the inflammation and in the coagulation process in general; correlation of inflammation with cancer; neurodegeneration; antioxidant activity; theoretical and experimental calculation of physicochemical parameters implicated in biological response; use of computational chemistry in drug design as well as bioactive compounds of natural origin, e.g., essential oils
Special Issues and Collections in MDPI journals
Special Issue in Molecules: Curcumin an Example of Pleiotropic Agents—Design, Synthesis and Biological Evaluation of Curcumin Analogues or Curcumin Derivatives
Special Issue in Molecules: Anti-inflammatories against Neurodegenerative Diseases
Special Issue in Molecules: Synthesis and Pharmacochemistry of New Pleiotropic Pyrrolyl Derivatives
Topical Collection in International Journal of Molecular Sciences: Orphan Drugs
Special Issue in International Journal of Molecular Sciences: Curcumin Derivatives and Curcuminoids as Theranostic Agents in Alzheimer’s Disease
Lipases and phospholipases govern mammalian metabolism. They share many common features; however, they differ from other metabolic enzymes. Their potential as drug targets for the treatment of metabolic diseases, cancer, atheromatosis, neurogenerative diseases and inflammation is widely recognized, and the first lipase inhibitor drugs have been successfully introduced.
The potential for phospholipases as targets for treating atherogenesis has become more prominent over the past year with the publication of the results of Phase 2 clinical trials of two inhibitors of forms of phospholipase A2: darapladib (GSK), which inhibits lipoprotein-associated phospholipase A2 and varespladib (Anthera) an inhibitor of several secreted phospholipase A2s.
Phospholipase A2 is a known mediator of inflammation, atherosclerosis and cancer in mammals. Inhibition of PLA2 alters cancer. It, therefore, makes the enzyme a potential drug target. Furthermore, phospholipases can be used for liposome-based drug delivery and as diagnostic tools.
Prof. Dr. Dimitra Hadjipavlou-Litina
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- phospholipase inhibitors
- lipase inhibitors
- drug targets
- secreted phospholipase
- serine lipase